跳至主要内容
临床试验/NL-OMON41390
NL-OMON41390已完成不适用

Pharmacogenetics of Asthma Medication in Children: Medication with Anti-inflammatory effects with special focus on Neutrophils. - Pacman-cohort

niversiteit Utrecht0 个研究点目标入组 1,010 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,010

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
2 至 17(—)

入选标准

  • - Use R03 drugs
  • - Age between 4-12 years
  • - Parents able to speak, read and write Dutch language
  • - At least 2 years of medication history available in which the child filled >=1 prescriptions for any asthma drug (RO3) within the last 6 months and at least 2 prescriptions in the last 12-24 months;For PACMAN phase 2 we will select a subgroup of these patients;
  • - parents consented to be approached for future research
  • - child is 8 years or older
  • - child is adherent to ICS
  • - child is classified as a non-responder (case) or responder to asthma medication (control)

排除标准

  • - child is younger than 8 years
  • - child does not use ICS
  • - child is not adherent to ICS
  • - consent is not obtained to be approached for future research during phase 1

研究者

相似试验